Apellis Files 8-K on Financials and Other Events
Ticker: APLS · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1492422
Sentiment: neutral
Topics: 8-K Filing, Financial Reporting, Corporate Update
TL;DR
**Apellis filed an 8-K covering financials and other events, but the details aren't in this snippet.**
AI Summary
Apellis Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, to report on its "Results of Operations and Financial Condition," "Other Events," and "Financial Statements and Exhibits." The filing, with SEC File Number 001-38276, indicates that the company is providing updates on these key areas. However, the provided text only contains the filing's metadata and does not include the specific details of the financial results or other events.
Why It Matters
This 8-K indicates Apellis Pharmaceuticals, Inc. is reporting on its financial condition and other significant events, which could impact investor perception and stock performance once the full details are released. Investors will need to review the complete filing to understand the specific implications.
Risk Assessment
Risk Level: low — The provided text is only a header and metadata for an 8-K filing, containing no specific financial or operational details that would indicate risk.
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Registrant
- February 27, 2024 (date) — Date of earliest event reported
- Delaware (state) — State of Incorporation
- 001-38276 (identifier) — Commission File Number
- 27-1537290 (identifier) — IRS Employer Identification Number
- 100 Fifth Avenue Waltham, MA 02451 (address) — Principal Executive Offices
- 617-977-5700 (phone_number) — Registrant's telephone number
- 0001492422 (identifier) — Central Index Key (CIK)
FAQ
What is the name of the company that filed this 8-K?
The company that filed this 8-K is Apellis Pharmaceuticals, Inc.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is February 27, 2024.
What specific items are indicated as being covered by this 8-K filing?
This 8-K filing indicates coverage of "Results of Operations and Financial Condition," "Other Events," and "Financial Statements and Exhibits."
What is the business address of Apellis Pharmaceuticals, Inc. as stated in the filing?
The business address of Apellis Pharmaceuticals, Inc. is 100 Fifth Avenue, Waltham, MA 02451.
What is the SEC file number for Apellis Pharmaceuticals, Inc.?
The SEC file number for Apellis Pharmaceuticals, Inc. is 001-38276.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-02-27 07:30:53
Key Financial Figures
- $426.1 million — a notional amount corresponding to the $426.1 million principal amount of Notes that the Comp
- $100 million — he unwind transactions of approximately $100 million. The unwind transactions will be settle
Filing Documents
- d796432d8k.htm (8-K) — 29KB
- d796432dex991.htm (EX-99.1) — 131KB
- g796432g0227061838075.jpg (GRAPHIC) — 2KB
- 0001193125-24-047073.txt ( ) — 297KB
- apls-20240227.xsd (EX-101.SCH) — 3KB
- apls-20240227_lab.xml (EX-101.LAB) — 17KB
- apls-20240227_pre.xml (EX-101.PRE) — 11KB
- d796432d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apellis Pharmaceuticals, Inc. Date: February 27, 2024 By: /s/ Timothy Sullivan Timothy Sullivan Chief Financial Officer